GlaxoSmithKline (NYSE:GSK), one of the big pharma companies hit hardest by the patent cliff, is trying to pull ahead by both innovating in the laboratories and innovating its research and development process. In this video, health-care analyst Max Macaluso discusses Glaxo's R&D structure and weighs in on what he expects to see from this drugmaker in 2013.